Evaxion A (EVAX) EBT Margin (2024 - 2025)
Evaxion A's (EVAX) quarterly EBT Margin came in at 58.09% in Q3 2025, up 12541.0% YoY from N/an in Q3 2024, and up 100.43% on a QoQ basis from 13583.78% in Q2 2025.
Evaxion A (EVAX) EBT Margin (2024 - 2025) Analysis & Trends
Evaxion A (EVAX) has 2 years of EBT Margin data on file, last reported at 58.09% in Q3 2025.
- Quarterly EBT Margin rose 12541.0% year-over-year to 58.09% in Q3 2025, while the trailing twelve-month figure through Mar 2026 was 142.02% (up 28024.0% YoY) and the FY2025 annual result came in at 114.44%, up 22512.0% from the prior year.
- EBT Margin improved to 58.09% in Q3 2025, from 13583.78% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1913.73% in Q1 2024 to a low of 13583.78% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Evaxion A | 26.86 Mn | 26.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 58.09% |
| Jun 30, 2025 | -13,583.78% |
| Dec 31, 2024 | -3,200.00% |
| Sep 30, 2024 | -67.32% |
| Jun 30, 2024 | -4,024.68% |
| Mar 31, 2024 | 1,913.73% |